Changes in Hormone Receptor and Her2 Status After Neoadjuvant Chemotherapy in Breast Cancer


Kaya A. O. , Buyukberber S., Yamac D., Coskun U., YILDIZ R. , Yaman E., ...Daha Fazla

TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, cilt.30, ss.469-473, 2010 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 30 Konu: 2
  • Basım Tarihi: 2010
  • Doi Numarası: 10.5336/medsci.2008-10066
  • Dergi Adı: TURKIYE KLINIKLERI TIP BILIMLERI DERGISI
  • Sayfa Sayıları: ss.469-473

Özet

Objective: Hormone receptor (HR) and Her2/neu expressions may change following neoadjuvant chemotherapy. The clinical significance of this receptor alteration is unclear. We retrospectively investigated the frequency of HR and Her2/neu status change in response to neoadjuvant chemotherapy. Material and Methods: Medical records of 49 patients with locally advanced breast cancer treated with anthracycline- and/or taxane-based neoadjuvant chemotherapy were retrospectively evaluated. The median age at diagnosis was 53 years (range, 27-79). All patients were operated within 3-4 weeks of the last cycle of chemotherapy. We also analyzed the relation of tumor marker alterations with patient outcome. Results: Alterations in hormonal receptor and Her2/neu protein expression were observed in 16 (32.6%) of the 49 patients. There was no statistically significant difference in HR expressions before and after neoadjuvant chemotherapy (p=NS). In addition, two (4%) patients with positive Her2/neu became Her2/neu negative after neoadjuvant chemotherapy. Twelve (24%) patients with negative estrogen and progesteron receptor expressions were converted to positive after neoadjuvant chemotherapy. There was no effect of HR alterations on patient outcome. Conclusion: HR and Her2/neu expression alterations are not infrequent in response to neoadjuvant chemotherapy. Tumor marker status determination in the final surgical specimen is recommended.